前往化源商城

1616632-80-4 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: IP6K1-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.

1. Reagent, 3 uL of 1.3 mM ATP and 130 uM IP6 mixture in assay buffer was dispensed to a white, 1536-well assay plate.
2. Compound, 23 nL of compounds of the top two doses (57.5 uM and 19.1 uM final concentration) of the libraries were dispensed into the mixture using the Kalypsis pintool.
3. Reagent, 1 uL of 2.4 uM IP6K1 was dispensed to the assay plates.
4. Incubation, 2 hr incubation at room temperature.
5. Reagent, 2 uL of ADP-Glo reagent was added to the wells.
6. Incubation, 1 hr incubation at room temperature.
7. Reagent, 4 uL or ADP-Glo substate was added to the wells.
8. Incubation, 45 min incubation at room temperature.
9. Detection, luminescence signal was detected using the ViewLux microplate imager (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Majority of the compounds were tested at 58uM and 11uM. Percent inhibition at 58uM (Max_Response) was obtained and used for compound ranking.
2. For all inactive compounds, with Max_Response >= -25.00, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds (Max_Response < -25.00, more than 25% inhibition) a score range was given between 25 and 100. The activity score is based on the absolute value of the Max_Response.
PhenotypeAnalysis CommentActivity_ScoreMax_ResponseActivity at 0.029 uMActivity at 0.115 uMActivity at 0.144 uMActivity at 0.230 uMActivity at 0.575 uMActivity at 1.257 uMActivity at 2.059 uMActivity at 2.870 uMActivity at 3.790 uMActivity at 5.750 uMActivity at 7.911 uMActivity at 11.54 uMActivity at 17.22 uMActivity at 25.95 uMActivity at 38.35 uMActivity at 57.50 uMActivity at 85.10 uMActivity at 115.2 uMActivity at 153.0 uMActivity at 245.0 uMActivity at 288.0 uMCompound QC
Inactive0-0.963.5361-0.96QC'd by Chemdiv
Inactive0-0.9559-3.6852-0.9559QC'd by Chemdiv
Inactive0-0.9553-5.7534-0.9553QC'd by Chemdiv
Inactive0-0.9545-5.6084-0.9545QC'd by ChemRoutes
Inactive0-0.953-2.3216-0.953QC'd by Sytravon
Inactive0-0.94922.2186-0.9492QC'd by Edelris
Inactive0-0.9486-1.2758-0.9486QC'd by Chemdiv
Inactive0-0.94674.4666-0.9467QC'd by ChemRoutes
Inactive0-0.9436-8.9932-0.9436QC'd by Chemdiv
Inactive0-0.9422-1.7826-0.9422QC'd by Analyticon
Inactive0-0.9415.2115-0.941QC'd by Chemdiv
Inactive0-0.93984.3972-0.9398QC'd by Sytravon
Inactive0-0.93624.3836-0.9362QC'd by Chemdiv
Inactive0-0.92992.8643-0.9299QC'd by Sytravon
Inactive0-0.92934.8772-0.9293QC'd by Chemdiv
Inactive0-0.9286-10.0521-0.9286QC'd by Chemdiv
Inactive0-0.9253-2.1742-0.9253QC'd by Sytravon
Inactive0-0.92040.4163-0.9204QC'd by Edelris
Inactive0-0.9193-0.0183-0.9193QC'd by Analyticon
Inactive0-0.9182-0.8109-0.9182QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: MTASE-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent; 2 uL; SMMTase Enzyme (2x) in reaction buffer, columns 1- 48.
2; Reagent; 1 uL; SAM (4x) in reaction buffer, columns 1-48.
3; Controls; 23 nL; DMSO in column 4; sinefungin in DMSO (0 uM - 40 uM) in 7-point 1:2 dilution series (n = 2) in column 2.
4; Compounds; 23 nL; Columns 5-48.
5; Reagent; 1 uL; Substrate (4x) in reaction buffer, columns 2-48.
6; Time; 20-30 min; Incubation.
7; Reagent; 1 uL; MTase-Glo reagent (5X), columns 1-48.
8; Time; 30 min; Incubation.
9; Reagent; 5 uL; MTase-Glo Detection reagent, columns 1-48.
10; Time; 30 min; Incubation, luminescence evolution.
11; Detection; Luminescence; ViewLux uHTS Microplate Imager (PerkinElmer).

NOTES (numbers refer to Sequence numbers above)
1, 2, 5. White Medium Binding Greiner 1536-well plates (Cat #789175-F, Greiner Bio-One, Monroe, NC); Reaction buffer: 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA. Evaporation was prevented by covering assay plates with metal lids containing holes to allow gas diffusion.
1. Six SMMTase were profiled: HNMT, GNMT, PNMT, COMT, NNMT, GAMT
2. The corresponding SAM cofactor concentration was used for each SMMTase: HNMT - 9.3 uM SAM; GNMT - 12.1 uM SAM; PNMT - 3.6 uM SAM; COMT - 14.5 uM SAM; NNMT 11.9 uM SAM; GAMT - 5.6 uM SAM.
3, 4. Pintool transfer
5. The corresponding substrate was used for each enzyme: HNMT - 5.3 uM Histamine; GNMT - >500 uM Glycine; PNMT - 16.2 uM Norephinephrine; COMT - 13.7 uM Norephinephrine; NNMT - 3.8 uM Nicotinamide; GAMT - 2.5 uM Guanidinoacetate.6, 8, 10. Room temperature
6. Final reaction conditions: 10 nM COMT, 5 uM SAM, 15 uM norepinephrine, 50 mM Tris, pH 8.0, 3 mM MgCl2, 1 mM EDTA, 50 mM NaCl, 1 mM DTT, and 0.1 mg/mL BSA; refer to tables 2 and S1 for specific timing.
8. Conversion of SAH to ADP; MTase Glo Kit (Promega, Madison, WI).
10. Conversion of ADP to ATP and detection by UltraGlo luciferase; MTase Glo Kit (Promega, Madison, WI).
11. Settings: 20 s exposure, 1X binning, high gain, medium speed.

REFERENCES:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are assayed at single point activity (40 uM).
2. Active / Inactive compound calling is based on the results of the enzyme assay panel. ACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 50 and are compounds that have <= -50% max response in ANY ONE of the six enzymes. INACTIVE compounds have PUBCHEM_ACTIVITY_SCORE = 0 and are those that have >= -30% max response in ALL SIX enzymes. The remaining compounds are INCONCLUSIVE and have PUBCHEM_ACITIVITY_SCORE = 30.
COMT-Max_ResponseGAMT-Max_ResponseGNMT-Max_ResponseHNMT-Max_ResponseNNMT-Max_ResponsePNMT-Max_Response
-14.477-0.906-64.36-7.723-13.221-6.568
-97.283-96.83-99.246-99.097
-11.662-7.108-69.542-15.105-18.57-11.209
9.957-8.37-63.807-27.029-13.633-0.512
-1.3788.081-1.801-70.001-9.255-2.174
-4.184-8.838-45.186-20.976-17.93-50.762
-64.186-17.487-82.517-23.323-14.889-4.424
-28.27-13.82-44.132-13.042-22.645-61.981
-95.9186.395-70.158.26-8.601-15.867
-6.366.696-61.41910.286-22.134-20.539
2.7649.187-5.281.889-50.6463.945
5.467.241-52.1632.748-5.3684.271
18.645-5.1-85.869-4.46517.42
-33.223-8.861-69.978-8.649-22.429-13.542
-22.681-17.904-81.69-53.866-21.453-18.314
3.649-5.536-6.193-64.526-18.858-7.356
-17.938-19.922-61.7-32.188-41.884-42.419
-0.0336.8778.069-87.187-3.6082.522
66.24812.293-50.945-8.947-3.8437.458
-0.7140.817-11.379-86.711-10.789-2.627
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A4437
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-8.32134.95490.64234-4.834640 0 0 0 0 0 1-4.4443-2.77887.36895.36932.33973.33831.6715-4.4443QC'd by Sytravon0
Inhibitor2.391969.704984Complete curve; high efficacy-5.62130.90.993-69.49290.212-1.10 0 0 0 0 0 0-66.6604-0.25131.2197-5.3806-9.9311-37.162-53.3921-66.6604QC'd by Sytravon0
Inhibitor9.522176.407442Partial curve; high efficacy-5.02131.1110.9951-75.90940.498-2.10 0 0 0 0 0 0-66.59123.4283-1.6815-1.5622-0.1199-13.7121-41.7015-66.5912QC'd by Sytravon0
Inactive0-4.52131.75290.9212-24.98775.540 0 0 0 0 0 0-17.48977.36232.46169.84163.36053.96510.8896-17.4897QC'd by Sytravon0
Inhibitor1.5092115.26487Complete curve; high efficacy-5.82131.46410.9934-109.85685.4073-1.10 0 0 0 0 0 0-110.2979-0.81499.86343.518-7.3368-73.6123-100.848-110.2979QC'd by Sytravon0
Inhibitor1.6933117.978187Complete curve; high efficacy-5.77134.50450.9912-112.735.2481-1.10 0 0 0 0 0 0-115.265815.93722.4103-1.24092.2518-88.9575-109.7932-115.2658QC'd by Sytravon0
Inhibitor4.772481.295643Partial curve; high efficacy-5.321310.9946-78.60572.6899-2.10 0 0 0 0 0 0-71.671-0.64476.43020.1885-3.4582-24.3313-55.7062-71.671QC'd by Sytravon0
Inhibitor7.563794.395183Complete curve; high efficacy-5.12134.95490.9967-94.6258-0.2307-1.10 0 0 0 0 0 0-93.87483.4317-2.5012-1.7201-2.44552.6182-85.3984-93.8748QC'd by Sytravon0
Inhibitor2.683765.029784Complete curve; high efficacy-5.57134.0950.989-65.3833-0.3537-1.10 0 0 0 0 0 0-70.4739-2.312-0.8042-1.22813.0628-22.6396-60.696-70.4739QC'd by Sytravon0
Inhibitor7.563757.206142Partial curve; partial efficacy-5.12131.62590.9942-54.13193.0742-2.20 0 0 0 0 0 0-52.30876.2072.82521.47620.0987-3.9796-35.0702-52.3087QC'd by Sytravon0
Inhibitor1.198874.619785Complete curve; high efficacy-5.92131.13410.9933-70.92043.6993-1.10 0 0 0 0 0 0-71.49064.2219-0.18864.5237-17.1469-46.9199-63.4145-71.4906QC'd by Sytravon0
Inhibitor2.1317118.451686Complete curve; high efficacy-5.67132.72020.993-110.08868.3631-1.10 0 0 0 0 0 0-116.12727.57825.10285.881412.5352-56.6231-102.2879-116.1272QC'd by Sytravon0
Inhibitor2.1317122.703187Complete curve; high efficacy-5.67132.40640.9787-115.72726.9759-1.10 0 0 0 0 0 0-122.07513.858917.443-6.083311.7009-62.2871-106.7609-122.0751QC'd by Sytravon0
Inhibitor6.7412121.082984Complete curve; high efficacy-5.17134.0950.9954-126.4671-5.3842-1.10 0 0 0 0 0 0-126.975-0.8069-3.4445-2.4548-11.8834-10.2564-113.7668-126.975QC'd by Sytravon0
Inhibitor4.772486.82744Partial curve; high efficacy-5.321310.9941-85.3831.444-2.10 0 0 0 0 0 0-78.6992-2.43161.8612-0.004-1.8987-28.5107-58.6303-78.6992QC'd by Sytravon0
Inhibitor7.5637125.15484Complete curve; high efficacy-5.12133.92950.9979-122.58722.5668-1.10 0 0 0 0 0 0-123.07953.09863.12671.8871-2.10935.2605-101.0355-123.0795QC'd by Sytravon0
Inhibitor0.6741119.919989Complete curve; high efficacy-6.17131.37230.9986-109.745410.1745-1.10 0 0 0 0 0 0-110.8548.84597.74156.7576-35.5397-88.9969-106.7803-110.854QC'd by Sytravon0
Inhibitor6.7412115.981384Complete curve; high efficacy-5.17132.30310.9963-113.59672.3846-1.10 0 0 0 0 0 0-113.37-1.2322-1.59845.85995.7708-6.0722-86.9448-113.37QC'd by Sytravon0
Inhibitor1.5092114.050988Complete curve; high efficacy-5.82131.96730.9946-113.91580.1351-1.10 0 0 0 0 0 0-113.0117-0.8223-4.0553-2.3728-1.6822-81.3904-111.2484-113.0117QC'd by Sytravon0
Inhibitor8.486660.792742Partial curve; partial efficacy-5.07132.40640.9868-57.96392.8287-2.20 0 0 0 0 0 0-56.54736.87814.87661.3348-2.20081.3516-39.1581-56.5473QC'd by Sytravon0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: OBG420
Protocol: Assay Protocol Summary:

1,000 cells in 4 uL of media were dispensed into white, solid bottom 1536-well plates using a Multidrop Combi (Thermo Scientific). The Assay plates were incubated for 16 hours at 37 C with 5% CO2 in assay plates, followed by the addition of 23 nL of DMSO or drug dissolved in DMSO. Each compound was assayed in five concentrations (0.092, 0.46, 2.3, 11.5, and 57.5 uM), using the automated Wako 1536 Pin Tool workstation and incubated at 37 C with 5% CO2 48 hours. 4 uL of ATPlite, the ATP monitoring reagent, was then added to the each well of the assay plates using the Multidrop Combi reagent dispenser followed by incubation for 15 minutes at room temperature. The resulting luminescence was measured using the ViewLux plate reader.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, cytotoxic compounds are considered active and show up as apparent inhibitors, which are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0002299000 uMActivity at 0.0009353959 uMActivity at 0.00184 uMActivity at 0.00468 uMActivity at 0.00919 uMActivity at 0.016 uMActivity at 0.027 uMActivity at 0.051 uMActivity at 0.092 uMActivity at 0.155 uMActivity at 0.256 uMActivity at 0.462 uMActivity at 0.846 uMActivity at 1.283 uMActivity at 2.310 uMActivity at 4.246 uMActivity at 6.551 uMActivity at 11.58 uMActivity at 25.26 uMActivity at 38.52 uMActivity at 57.54 uMActivity at 116.1 uMActivity at 221.6 uMActivity at 288.3 uMPanel IDPanel Name
Inactive0.089120.43770-7.054.95490.524316-4.437740 0 0 0 013.1195-1.614723.02214.923222.436413.11953PA-1
Inactive0.501219.5120-6.34.50450.98372.5-17.01240 0 0 0 04.6148-17.0933-15.1392.02030.96314.61484SKOV3
Inactive0.089110.17840-7.054.95490.4664-7.67842.540 0 0 0 0-7.22470.9983-11.3986-10.48-0.961-7.22475C33A
Inactive000046.8018-1.79437.92887.71697.15576.80186JEG-3
Inactive0.6315.87540-6.24.95490.65335-0.875440 0 0 0 04.99780.7404-1.97958.09512.36074.99787Es-2
Inactive00004-1.56592.9339-4.8958-4.79511.5969-1.56598Hek293T
Inactive0.08919.9950-7.054.95490.3786-7.4952.540 0 0 0 0-5.41281.1477-11.5205-0.3743-12.9125-5.41289Tov112D
Inactive00004-3.29573.83081.4062-4.436-2.7163-3.295710Tov-21-G
Inactive0.707914.66040-6.154.95490.999411.5-3.160440 0 0 0 11.8313-3.0503-3.035511.111111.20241.831311OV90
Inactive2.511911.03920-5.61.62590.99184.5-6.539240 0 0 0 04.3244-5.7563-6.6993-3.04413.02174.324412CASKI
Inactive000044.00029.26091.730716.16898.27064.00021CAOV3
Inactive0.112.42240-71.64360.8881-1.922410.540 0 0 0 0-4.51867.76070.4819-0.6217-0.7957-4.51862HeLa
Inactive000049.02713.25131.741213.527517.68579.0273PA-1
Inactive0.3162180-6.54.44950.963772540 0 0 0 119.687125.203421.51315.01739.427119.68714SKOV3
Inactive000040.33690.4452-0.91255.72924.440.33695C33A
Inactive0.063110.50-7.24.95490.8451212.540 0 0 0 01.087910.83860.19022.46194.63951.08796JEG-3
Inactive0.50129.55980-6.34.95490.95170-9.559840 0 0 0 0-0.0179-8.4158-10.46650.9667-1.2439-0.01797Es-2
Inactive0.063114.81190-7.24.95490.534-5.8119940 0 0 0 10.28146.5861-12.75991.4268-6.08970.28148Hek293T
Inactive8.91258.5410-5.054.0450.6148-0.54140 0 0 0 07.75193.7595-4.2009-0.57340.66357.75199Tov112D
Inactive000041.0625-0.46660.2533-1.2691-7.13331.062510Tov-21-G
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2D6395
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (quinidine) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-7.260.70.983122040 0 0 0 0 0 0 018.72430.75090.74030.16150.22082.57129.062412.490518.7243QC'd by Labotest0
Inactive00043.08132.90954.18193.06831.54751.9993-1.48293.82823.0813QC'd by Labotest0
Inhibitor10.96462.697110Partial curve; high efficacy; poor fit-4.964.95490.998-66.9977-4.3007-2.31 0 0 0 0 0 0 0-65.7875-42.8846-3.6636-4.8429-3.3836-3.8623-4.4736-41.4229-65.7875QC'd by Microsource0
Inhibitor38.901833.850110Partial curve; partial efficacy; poor fit-4.414.95490.924-33.35010.5-2.40 0 0 0 0 0 0 0-29.0418-1.55510.52060.875-1.2476-0.5605-1.80927.4199-29.0418QC'd by SIGMA0
Inhibitor1.737781.229885Complete curve; high efficacy-5.761.96730.9976-79.95641.2734-1.10 0 0 0 0 0 0 0-78.3324.47950.76060.0181-0.701-3.7995-49.0322-80.0522-78.332QC'd by Tocris0
Inhibitor34.671337.231710Partial curve; partial efficacy; poor fit-4.462.35310.9195-37.23170-2.40 0 0 0 0 0 0 0-28.52643.96925.0423-3.0201-3.1048-1.1738-0.8348-2.4447-28.5264QC'd by Microsource0
Inhibitor15.487171.27341Partial curve; high efficacy-4.811.44870.9928-70.41130.8617-2.10 0 0 0 0 0 0 0-61.76430.28531.9381-1.2811-0.34364.6186-4.2001-27.4432-61.7643QC'd by GVK0
Inhibitor0.218891.972890Complete curve; high efficacy-6.660.80.9894-90.01021.9626-1.10 0 0 0 0 0 0 0-83.87692.77070.8657-14.6874-27.4321-55.0254-79.0233-92.6031-83.8769QC'd by Prestwick Chemical; Inc.0
Inhibitor34.671345.828810Single point of activity-4.462.35310.9938-45.82880-30 0 0 0 0 0 0 0-35.0976-0.4182-0.112-0.91482.1786-0.5211-0.77-3.3082-35.0976QC'd by Vitas0
Inhibitor13.8029116.598142Partial curve; high efficacy-4.860.70.9704-115.4741.1242-2.10 0 0 0 0 0 0 0-87.4803-1.2071.2781-1.1552-1.0641-0.761-34.877-47.6739-87.4803QC'd by Vitas0
Inhibitor19.497171.169541Partial curve; high efficacy-4.712.33320.9649-71.6292-0.4597-2.10 0 0 0 0 0 0 0-66.007-7.5073.5896-6.58233.21022.04942.4442-17.4355-66.007QC'd by Enzo0
Inactive0004-0.33970.68341.1935-3.1601-7.1353-6.692-3.5353-4.6055-0.3397QC'd by Microsource0
Inhibitor38.901899.707710Single point of activity-4.412.90230.9979-103.2475-3.5398-30 0 0 0 0 0 0 0-78.9754-2.6538-1.9475-2.4198-3.036-5.7354-4.4174-6.1242-78.9754QC'd by Labotest0
Inactive00040.55794.29663.86970.9141.57842.77632.2827-0.27460.5579QC'd by Microsource0
Inactive0004-2.28934.50485.93892.79056.12561.13645.75735.7586-2.2893QC'd by Tocris0
Inhibitor12.301842.282721Partial curve; partial efficacy-4.912.33320.9667-45.1528-2.8702-2.20 0 0 0 0 0 0 0-43.5551-8.1379-5.4062-0.92150.1464-0.2747-3.1761-22.7908-43.5551QC'd by Labotest0
Inactive00042.7074-0.37290.3242.07662.64641.1615-0.70884.47812.7074QC'd by Prestwick0
Inactive0004-1.99643.70481.65273.62083.19225.03624.9342-1.7586-1.9964QC'd by Microsource0
Inactive0-6.360.80.89615-7.047740 0 0 0 0 0 0 04.9227-4.8515-7.6164-8.7898-3.26990.29170.34185.50584.9227QC'd by VitasInactive00
Inhibitor3.4671109.162545Partial curve; high efficacy-5.460.90.9982-103.53135.6312-2.10 0 0 0 0 0 0 0-96.39795.98693.1773.47834.7559-9.3266-39.4946-74.1667-96.3979QC'd by Enzo0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2C9536
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix supplemented with 0.4% Bovine Serum Albumin was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (sulfaphenazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at 37C for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inhibitor21.317485.520741Partial curve; high efficacy-4.67133.19250.957-74.520711-2.10 0 0 0 0 0 0-71.26736.65818.66165.03429.029624.68310.5948-71.2673QC'd by Microsource0
Inactive00040.31867.0625.1975.69257.23591.2670.52010.3186QC'd by Microsource0
Inhibitor7.563793.544743Partial curve; high efficacy-5.12131.92820.9984-89.27954.2653-2.10 0 0 0 0 0 0-87.52897.16565.07882.79792.1575-3.7741-60.4613-87.5289QC'd by Tocris0
Inhibitor26.83748.635610Single point of activity-4.57132.24810.9788-42.84845.7872-30 0 0 0 0 0 0-35.46775.96295.47962.709210.27554.6543-0.1967-35.4677QC'd by NCI0
Inhibitor8.4866130.766843Partial curve; high efficacy-5.071310.9992-119.896710.8701-2.10 0 0 0 0 0 0-102.475811.946611.24277.15545.0781-16.0537-65.0649-102.4758QC'd by BIOMOL0
Inhibitor5.354799.189644Partial curve; high efficacy-5.27130.90.9888-96.57122.6185-2.10 0 0 0 0 0 0-87.001-0.2592-1.6376.8143-4.5159-32.2161-61.4841-87.001QC'd by BIOMOL0
Inactive0-4.67132.33320.6923-15.1448-0.540 0 0 0 0 0 0-13.8707-3.7401-1.27785.1005-4.69041.916-3.5213-13.8707QC'd by InterBioScreen0
Inhibitor25.401256.202240Partial curve; partial efficacy-4.59514.50450.9727-57.7888-1.5865-2.20 0 0 0 0 0 0 0-57.6748-1.4876-4.4957-6.22962.86763.1906-3.7494-18.0858-57.6748QC'd by LightBiologicalsInhibitor40.258241.12110Single point of activity-4.39512.95230.943-42.7254
Inhibitor7.563797.471243Partial curve; high efficacy-5.12131.92820.9955-91.45176.0195-2.10 0 0 0 0 0 0-89.13426.42811.19024.98681.8065-2.3315-62.2028-89.1342QC'd by Tocris0
Inhibitor21.317476.663841Partial curve; partial efficacy-4.67131.24750.9713-70.16386.5-2.20 0 0 0 0 0 0-53.059711.862810.1962-0.30794.2931.9517-17.9254-53.0597QC'd by SigmaAldrich0
Inhibitor26.837101.665640Partial curve; high efficacy-4.57131.59360.9916-96.27045.3952-2.10 0 0 0 0 0 0-73.31095.62388.78586.24482.4666-0.9326-13.5438-73.3109QC'd by Tocris0
Inhibitor3.790887.146544Partial curve; high efficacy-5.42130.80.9942-85.19521.9512-2.10 0 0 0 0 0 0-78.88451.4625-1.87161.6032-10.9203-35.4628-58.552-78.8845QC'd by Tocris0
Inhibitor37.9083129.914810Single point of activity-4.42134.95490.9896-129.29750.6173-30 0 0 0 0 0 0-114.6255-1.4437-2.5082-0.90198.8381-4.54583.1106-114.6255QC'd by SigmaAldrich0
Inhibitor26.837109.062140Partial curve; high efficacy-4.57131.34370.9459-109.3538-0.2917-2.10 0 0 0 0 0 0-82.84382.53255.07320.78280.5149-19.3744-20.4297-82.8438QC'd by Bosche0
Inactive0-4.412.90230.8395-17.3952-0.540 0 0 0 0 0 0 0-13.246-3.84691.9539-0.2562-2.65371.4770.7446-0.9487-13.246QC'd by ACC0
Inactive0-8.363.1320.36283-4.516440 0 0 0 0 0 0 02.109-4.1803-1.83775.2557-1.05048.3001-3.10856.7452.109QC'd by Pharmaron0
Inactive00040.5041-8.57852.70450.1138-10.58420.93582.08840.5041QC'd by Toronto Research0
Inhibitor44.493235.276510Single point of activity-4.35173.67720.8478-34.72730.5492-30 0 0 0 0 0 0 0-32.3137-1.4989-3.7044-1.139-0.492412.1946-1.1884-3.139-32.3137QC'd by RTI0
Inactive00046.63087.63316.0247.39860.22633.18743.42856.6308QC'd by Tocris0
Inactive00045.326112.576410.112211.536311.2627.1953.95915.3261QC'd by NCGCChem0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-2C
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inactive00049.3597000002.228909.3597QC'd by Microsource
Inactive0-4.4754.95490.8748-21.4867440 0 0 0 0 0 0 0-17.07226.10422.829307.402506.12865.2151-17.0722QC'd by Vitas
Inactive0-8.2751.17050.66112-6.66740 0 0 0 0 0 0 0-1.0776-6.3892-2.9698-1.73725.8740.35322.4192.3477-1.0776QC'd by Labotest
Inactive0-4.4254.95490.4933-23.5282-340 0 0 0 0 0 0 0-17.94020.3948-8.1012-10.4184-5.55441.8102-4.77655.7051-17.9402QC'd by Vitas
Inactive000407.8331009.349608.39368.85740QC'd by Sequoia
Inactive000402.13462.08732.87872.198101.071700QC'd by SIGMA
Inactive000406.747707.7196.37060000QC'd by Prestwick
Inactive00041.32598.1273007.30856.14859.763401.3259QC'd by Enzo
Inactive0-6.7754.95490.7871-25.4234-14.789241 0 0 0 0 0 0 1-14.8266-40.4001-18.8558-14.3881-11.9076-28.2695-23.675-23.6904-14.8266QC'd by Microsource
Inactive00040003.22385.382307.503400QC'd by Microsource
Inactive0-4.4754.95490.4377-10.0741240 0 0 0 0 0 0 0-7.9784006.8904-2.128300.76149.8865-7.9784QC'd by Labotest
Inactive0004-2.11844.73944.4107-0.61385.167402.3218-1.3941-2.1184QC'd by Microsource
Inactive000400.23422.97255.131802.023500.05890QC'd by Enzo
Inactive0-8.7250.60.79454.5-11.988640 0 0 0 0 0 0 1-9.0185-8.3238-0.45670.90310.07213.33947.72623.0826-9.0185QC'd by Vitas
Inactive0-9.1254.95490.55695-5.355240 0 0 0 0 0 0 1-2.6103-2.7966.99953.42281.61018.09837.01342.0138-2.6103QC'd by Specs
Inactive00040.9896009.6344004.278600.9896QC'd by GVK
Inactive0-5.5254.0950.6337-3.6963340 0 0 0 0 0 0 0-3.46713.29266.721104.917102.2046-3.4969-3.4671QC'd by Prestwick
Inactive00043.12693.073206.53832.82740-3.41288.31143.1269QC'd by Labotest
Inactive0004002.5786.65920003.36630QC'd by Prestwick
Inactive00042.6761008.9375000.40802.6761QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NSD2-synergy-p-9B
Protocol: High-throughput drug screening of isogenic RCH-ACV cell lines was performed at the National Center for Advancing Translational Science (NCATS), National Institutes of Health as previously described (1). Briefly, isogenic RCH-ACV NSD2 p.E1099K mutant (9B) and WT cells (2C) were plated at 500 cells/well in a 1536-well plate with a 72-hour incubation with compounds prior to addition of CellTiter-Glo to assess cell viability. NCATS libraries screened include: NPC, MIPE 5.0, Kinase and NPACT. To determine compound activity in the qHTS assay, the concentration-response data for each sample was plotted and modeled by a four-parameter logistic fit yielding IC50 and efficacy (maximal response) values. The area under the curve (AUC) of the dose-response curve ensures both efficacy (magnitude of cell killing) and potency (concentration that elicits cell killing) are accounted for in the analysis of activity.

Reference:
1. Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Mol Pharmacol. 2019, Nov;96(5):629-640.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062633 uMActivity at 0.0000234000 uMActivity at 0.0000299492 uMActivity at 0.0000680174 uMActivity at 0.0001469594 uMActivity at 0.0003236290 uMActivity at 0.0006759500 uMActivity at 0.00129 uMActivity at 0.00271 uMActivity at 0.00485 uMActivity at 0.00758 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.399 uMActivity at 1.898 uMActivity at 4.965 uMActivity at 9.229 uMActivity at 17.27 uMActivity at 44.90 uMActivity at 91.89 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Inhibitor0.001595.0131100Complete curve; high efficacy-8.82954.95490.995-92.98592.0272-1.10 0 0 0 0 0 0 0 0 0 0-96.2587-1.6791-84.9271-90.9202-90.8631-90.7375-92.2911-92.6732-94.1019-94.0673-96.0913-96.2587QC'd by SIGMA
Inhibitor0.001796.0144100Complete curve; high efficacy-8.76833.24750.9987-95.37860.6358-1.10 0 0 0 0 0 0 0 0 0 0-96.92941.7123-0.1391-34.4453-93.3159-93.9442-94.1795-94.3745-94.7424-94.9325-95.6129-96.9294QC'd by MedChem Express
Inhibitor0.0017101.1335100Complete curve; high efficacy-8.76834.50450.9988-96.45574.6778-1.10 0 0 0 0 0 0 0 0 0 0-98.62542.93835.3252-23.8352-93.6078-94.3407-94.7755-96.5382-96.9802-98.093-97.488-98.6254QC'd by MedChem Express
Inhibitor0.001495.7664100Complete curve; high efficacy-8.86833.06540.9932-91.73124.0352-1.10 0 0 0 0 0 0 0 0 0 0-94.373606.5073-50.3576-85.2142-89.4583-90.3553-90.6328-93.2878-91.6178-92.6738-94.3736QC'd by MedChem Express
Inhibitor0.002792.056799Complete curve; high efficacy-8.5753.990.9971-93.082-1.0254-1.10 0 0 0 0 0 0 0-97.5703-1.153-56.5542-91.9507-92.331-93.0234-92.9105-92.2466-97.5703QC'd by Alfa Aesar
Inhibitor0.002786.152899Complete curve; high efficacy-8.5754.95490.9984-92.0573-5.9045-1.10 0 0 0 0 0 0 0-92.9872-5.0961-62.3948-91.5014-91.2009-92.0539-90.8793-91.9519-92.9872QC'd by Microsource
Inhibitor0.002198.487899Complete curve; high efficacy-8.6754.50450.9983-91.97956.5083-1.10 0 0 0 0 0 0 0-94.04855.8681-73.3835-89.9758-90.798-91.9458-91.2065-93.7497-94.0485QC'd by Bosche
Inhibitor7.0E-482.733499Complete curve; high efficacy-9.1750.60.8847-82.65670.0767-1.10 0 0 0 0 0 0 0-94.3569-37.5208-62.7186-72.7916-74.3825-79.8918-76.6331-78.5528-94.3569QC'd by Selleck
Inhibitor0.003795.081999Complete curve; high efficacy-8.43621.22210.9994-94.52050.5614-1.10 0 0 0 0 0 0-93.7704-1.16310.6157-11.9264-47.6173-82.383-92.7843-93.7704QC'd by Adooq
Inhibitor0.003394.047999Complete curve; high efficacy-8.47953.51170.9958-93.96230.0856-1.10 0 0 0 0 0 0 0 0 0 0-97.87741.2665-23.1756-88.8678-90.2585-91.8229-92.3997-94.1271-95.2991-93.6757-95.8566-97.8774QC'd by MedChem Express
Inhibitor0.0047102.007598Complete curve; high efficacy-8.32952.24810.997-94.17637.8312-1.10 0 0 0 0 0 0 0 0 0 0-98.71735.6987-9.7434-65.3554-90.638-91.2058-92.371-92.7427-94.2549-94.3053-96.979-98.7173QC'd by GVK
Inhibitor0.0047100.42998Complete curve; high efficacy-8.3253.67720.9994-93.22767.2013-1.10 0 0 0 0 0 0 0-94.74358.1328-8.6557-90.5176-92.1158-93.5383-93.4255-92.4974-94.7435QC'd by Prestwick
Inhibitor0.003896.763498Complete curve; high efficacy-8.4253.990.9994-92.02054.743-1.10 0 0 0 0 0 0 0-93.51674.0536-21.1619-91.8053-91.1174-91.9789-90.7784-91.2901-93.5167QC'd by Selleck
Inhibitor0.004590.539798Complete curve; high efficacy-8.34664.50450.9995-92.4565-1.9167-1.10 0 0 0 0 0 0-93.156-4.128-89.5728-91.2217-93.3904-92.524-93.0057-93.156QC'd by Selleck
Inhibitor0.005298.298798Complete curve; high efficacy-8.2884.95490.9993-92.65815.6406-1.10 0 0 0 0 0 0-93.59410-91.9394-91.381-91.3804-93.5391-93.3571-93.5941QC'd by ChemieTek
Inhibitor0.005298.854698Complete curve; high efficacy-8.2880.60.9861-94.11974.7349-1.10 0 0 0 0 0 0-93.9318-33.6729-64.3585-76.1096-84.2151-92.4038-93.1111-93.9318QC'd by MedChem Express
Inhibitor0.00486.042698Complete curve; high efficacy-8.39924.50450.9996-92.288-6.2454-1.10 0 0 0 0 0 0-91.795-7.0299-86.4668-91.4418-93.2202-92.6549-92.4417-91.795QC'd by Selleck
Inhibitor0.004698.020398Complete curve; high efficacy-8.3383.51170.9996-93.16844.8519-1.10 0 0 0 0 0 0-93.7644-11.8828-91.4502-92.2553-94.1095-92.9439-93.2642-93.7644QC'd by SIGMA
Inhibitor0.0042104.449798Complete curve; high efficacy-8.37954.95490.9968-93.920410.5293-1.10 0 0 0 0 0 0 0 0 0 0-96.62598.66757.5142-90.2575-91.0844-91.1114-92.6871-93.2743-95.4523-94.079-95.5345-96.6259QC'd by BioAustralis
Inhibitor0.004294.942198Complete curve; high efficacy-8.37952.84730.9968-94.75910.183-1.10 0 0 0 0 0 0 0 0 0 0-96.93990.6808-16.1375-78.234-91.1234-91.9081-92.3507-95.4781-97.4887-95.7111-95.4747-96.9399QC'd by ActiveBioChem
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: s-sky_synergy-MV-411_DR-CTG72-MIPE_NPC_NPACT_Kinase-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Media; 2uL; white, solid-bottom Corning assay plate.
2; Compounds; 23nL; Echo acoustic dispenser.
3; Cell; 5uL; 500 cells per well.
4: Incubation; 72hr; 37 C, 5% CO2, 95% humidity.
5; Reagent; 3uL; CellTiter-Glo reagent (Promega).
6; Incubation; 10min; room temperature.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above
1. Quantitative high-throughput screening (qHTS) of small molecule compounds was conducted on drug resistant SYKi MV4-11 cell line. Briefly, 2uL growth media (RPMI 1640 + 1% penicillin/streptomycin + 10% FBS) were added into an assay plate using a Multidrop Combi dispenser (Thermo Fisher Scientific).
2. Twenty-three nanoliter of small molecule compounds were added to each assay plates using the Echo acoustic dispenser (Beckman Coulter).
3. Cells were seeded into the assay plates at a final density of 500 cells in 5uL of media per well using the Multidrop Combi dispenser.
4. Plates were covered with stainless steel gasketed lids and incubated for 72 hours at standard cell culture conditions.
5. Viability was assessed by adding 3uL of CellTiter-Glo detection reagent (Promega).
6. Plates were covered with gasket lids and incubated for 10 minutes at room temperature.
7. Luminescence was measured on a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062652 uMActivity at 0.0000234000 uMActivity at 0.0000299754 uMActivity at 0.0000680318 uMActivity at 0.0001469781 uMActivity at 0.0003237363 uMActivity at 0.0006761082 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00486 uMActivity at 0.00759 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.356 uMActivity at 0.588 uMActivity at 1.402 uMActivity at 1.903 uMActivity at 4.972 uMActivity at 9.253 uMActivity at 17.29 uMActivity at 44.98 uMActivity at 91.90 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Cytotoxic0.00882.203484Complete curve; high efficacy-8.09921.010.966921.0427103.2462-1.10 0 0 0 0 0 013.188495.474859.067235.842331.665221.923822.070613.1884QC'd by Analyticon
Cytotoxic0.025981.057283Complete curve; high efficacy-7.58624.95490.92316.497297.5544-1.10 0 0 0 0 0 02.512597.003593.26858.94736.670723.420912.53742.5125QC'd by MedChem Express
Cytotoxic0.819985.290183Complete curve; high efficacy-6.08621.75290.99432.3577117.6478-1.10 0 0 0 0 0 034.7953115.2038115.6711122.1398.373449.123231.010634.7953QC'd by Glixx
Cytotoxic0.0190.438383Complete curve; high efficacy-7.99921.06410.985619.9781110.4164-1.10 0 0 0 0 0 013.8267101.704171.224135.805628.627925.082819.478713.8267QC'd by Analyticon
Cytotoxic0.0092105.836183Complete curve; high efficacy-8.03624.0950.998416.204122.0401-1.10 0 0 0 0 0 013.8473120.968928.848618.13117.368317.353714.687813.8473QC'd by SIGMA
Cytotoxic0.468384.095583Complete curve; high efficacy-6.32954.44950.96929.5128113.6083-1.10 0 0 0 0 0 0 0 0 0 021.2667108.9911100.6389111.6185114.5273123.8697121.846750.484436.16335.491326.950121.2667QC'd by MedChem Express
Cytotoxic0.104882.764282Complete curve; high efficacy-6.97951.41630.983812.632295.3964-1.10 0 0 0 0 0 0 0 0 0 010.575588.311793.092698.209696.743461.009638.863620.85115.78315.70359.904810.5755QC'd by BIOMOL
Cytotoxic0.177891.15582Complete curve; high efficacy-6.750.60.967113.9433105.0983-1.10 0 0 0 0 0 09.94996.781688.005652.483744.630729.767723.42539.949QC'd by Waterstone
Cytotoxic0.0106101.825682Complete curve; high efficacy-7.9752.72020.992711.1635112.9891-1.10 0 0 0 0 0 0 010.2995105.5432116.579542.386110.210110.828611.463311.646810.2995QC'd by Prestwick
Cytotoxic0.668497.583882Complete curve; high efficacy-6.1752.33320.990218.8259116.4097-1.10 0 0 0 0 0 0 015.8771121.1891108.6953122.087113.851596.846325.162623.985315.8771QC'd by Enzo
Cytotoxic0.042299.181282Complete curve; high efficacy-7.3751.34430.993310.554109.7352-1.10 0 0 0 0 0 0 010.7613114.3989100.783890.706544.474211.202813.845711.361610.7613QC'd by Tocris
Cytotoxic0.007584.106682Complete curve; high efficacy-8.1254.95490.99839.434493.541-1.10 0 0 0 0 0 0 06.535491.798594.110412.665511.09298.63279.997110.07546.5354QC'd by Bosche
Cytotoxic0.421785.920382Complete curve; high efficacy-6.3750.80.962221.4982107.4185-1.10 0 0 0 0 0 0 016.639100.4185107.3168112.829384.599367.881738.354237.879716.639QC'd by Vitas
Cytotoxic0.145895.744482Complete curve; high efficacy-6.83621.55790.976614.7016110.446-1.10 0 0 0 0 0 04.7392104.3625115.347884.378731.790525.599818.03364.7392QC'd by Microsource
Cytotoxic0.0036107.247382Complete curve; high efficacy-8.4444.95490.99898.6172115.8646-1.10 0 0 0 0 0 07.4398110.64829.223610.03329.4928.91416.32217.4398QC'd by Selleck
Cytotoxic0.163680.294782Complete curve; high efficacy-6.78622.04790.976317.79598.0898-1.10 0 0 0 0 0 06.7352100.462595.567485.02829.253227.68320.08926.7352QC'd by Selleck
Cytotoxic0.023197.640682Complete curve; high efficacy-7.63624.95490.999510.3864108.027-1.10 0 0 0 0 0 010.177107.94198.68449.835111.696111.67178.800110.177QC'd by Selleck
Cytotoxic1.587786.327482Complete curve; high efficacy-5.79921.3310.964223.21109.5374-1.10 0 0 0 0 0 029.2744118.455699.7114104.7412100.992385.097633.922129.2744QC'd by MedChem Express
Cytotoxic0.014689.488582Complete curve; high efficacy-7.83621.28760.99529.344198.8326-1.10 0 0 0 0 0 07.000590.702951.556722.53611.87749.85658.1887.0005QC'd by SynKinase
Cytotoxic0.006596.843182Complete curve; high efficacy-8.18624.0950.99488.9496105.7927-1.10 0 0 0 0 0 03.839102.120912.445311.444810.88219.89667.70273.839QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A7681
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Compounds dissolved in DMSO, and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073560 uMActivity at 0.0000367800 uMActivity at 0.0000735600 uMActivity at 0.0001677464 uMActivity at 0.0003678000 uMActivity at 0.0007363003 uMActivity at 0.00153 uMActivity at 0.00368 uMActivity at 0.00723 uMActivity at 0.00914 uMActivity at 0.018 uMActivity at 0.039 uMActivity at 0.092 uMActivity at 0.191 uMActivity at 0.460 uMActivity at 0.910 uMActivity at 1.182 uMActivity at 2.302 uMActivity at 4.834 uMActivity at 11.49 uMActivity at 23.94 uMActivity at 57.45 uMActivity at 115.4 uMActivity at 193.5 uMActivity at 288.3 uMCompound QC
Inhibitor1.0964121.524587Complete curve; high efficacy-5.960.60.996-99.00122.5235-1.10 0 0 0 0 0 0 0-91.416421.20118.089711.55633.2362-23.6097-54.3722-70.1237-91.4164QC'd by GVK
Inactive00041.30296.4095.7452-8.127411.434512.7995.91137.13891.3029QC'd by Vitas
Inhibitor0.05596.749490Complete curve; high efficacy-7.260.60.9836-74.157422.592-1.10 0 0 0 0 0 0 0-78.849512.345912.9899-11.4013-37.5586-53.042-61.5426-65.313-78.8495QC'd by Bosche
Inactive0004-9.339-4.094-2.86744.5071-4.4459-5.3433-2.46713.5091-9.339QC'd by BIOMOL
Inactive0-6.614.95490.77852.5-6.094140 0 0 0 0 0 0 1-8.7946-5.07-2.6335-5.97-10.49513.49112.05881.9174-8.7946QC'd by SIGMA
Inhibitor34.671339.82710Single point of activity-4.462.30310.825-41.327-1.5-30 0 0 0 0 0 0 0-31.93923.6009-5.26172.22954.1407-8.6455-6.9529-4.2362-31.9392QC'd by Microsource
Inactive040 0 0 0 0 0 0 0-13.898620.649216.42211.68939.501116.6467-2.6177-2.1673-13.8986QC'd by Vitas
Inhibitor15.487178.566741Partial curve; partial efficacy-4.810.80.995-76.6721.8947-2.20 0 0 0 0 0 0 0-58.08492.73420.67454.0214-0.609-3.975-12.9528-31.6593-58.0849QC'd by Sequoia
Inactive000426.644512.4429-0.644219.37847.33520.35134.22857.434426.6445QC'd by Microsource
Inactive0-5.92134.95490.79423.5-5.645240 0 0 0 0 0 1-9.4213-2.1113-8.4544-4.6822-8.22654.16062.7472-9.4213QC'd by Tocris
Inactive0004-2.8012-11.1342-2.1920-10.8176-0.6934-3.3166-1.4979-2.8012QC'd by SIGMA
Inactive0-5.764.95490.510428.8996-2.44840 1 0 0 0 0 0 1-2.30523.7377-36.8683-4.4543-19.5675-9.380122.243229.0984-2.305QC'd by Vitas
Inhibitor12.301887.401142Partial curve; high efficacy-4.910.60.9549-73.550113.8509-2.10 0 0 0 0 0 0 0-54.873522.14538.368412.13289.0141-1.3852-8.6537-22.9862-54.8735QC'd by Microsource
Inhibitor27.540450.239310Single point of activity-4.561.75290.9401-50.16480.0744-30 0 0 0 0 0 0 0-39.142.8036-3.03351.3596-6.01625.1159-1.7887-9.2175-39.14QC'd by Microsource
Inactive0-5.310.60.8041-16.01361740 0 0 0 0 0 0 0-11.67817.682513.435821.75976.519717.4375-0.6278-0.9036-11.678QC'd by Enzo
Inhibitor15.487177.547110Partial curve; partial efficacy; poor fit-4.811.1110.829-67.10610.4411-2.40 0 0 0 0 0 0 0-53.05410.743524.16552.70531.738225.7669-4.8999-19.2859-53.0541QC'd by Bosche
Inactive0-6.361.46410.8922-22.47584.540 0 0 0 0 0 0 0-25.49972.54256.30397.767-1.9911-6.3102-26.2299-15.2464-25.4997QC'd by Microsource
Inactive0-4.511.96730.4991426.540 0 0 0 0 0 0 016.846225.531732.670220.285228.569325.635926.981725.029716.8462QC'd by GVK
Inhibitor0.870947.278824Complete curve; partial efficacy-6.064.95490.9676-45.67661.6021-1.20 0 0 0 0 0 0 1-20.51278.27430.9756-1.5573-1.30970.8922-49.683-41.1152-20.5127QC'd by Enzo
Inactive0-6.064.95490.4399-0.676240 0 0 0 0 0 0 1-0.0131.95381.5464-4.31350.312-2.768216.93540.8252-0.013QC'd by Sequoia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: s-sky_synergy-MV-411_N-CTG72-MIPE_NPC_NPACT_Kinase-p1
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Media; 2uL; white, solid-bottom Corning assay plate.
2; Compounds; 23nL; Echo acoustic dispenser.
3; Cell; 5uL; 500 cells per well.
4: Incubation; 72hr; 37 C, 5% CO2, 95% humidity.
5; Reagent; 3uL; CellTiter-Glo reagent (Promega).
6; Incubation; 10min; room temperature.
7; Detection; Luminescence; ViewLux plate reader (PerkinElmer).

NOTES (numbers refer to Sequence numbers above
1. Quantitative high-throughput screening (qHTS) of small molecule compounds was conducted on naive SYKi MV4-11 cell line. Briefly, 2uL growth media (RPMI 1640 + 1% penicillin/streptomycin + 10% FBS) were added into an assay plate using a Multidrop Combi dispenser (Thermo Fisher Scientific).
2. Twenty-three nanoliter of small molecule compounds were added to each assay plates using the Echo acoustic dispenser (Beckman Coulter).
3. Cells were seeded into the assay plates at a final density of 500 cells in 5uL of media per well using the Multi-drop Combi dispenser.
4. Plates were covered with stainless steel gasketed lids and incubated for 72 hours at standard cell culture conditions.
5. Viability was assessed by adding 3uL of CellTiter-Glo detection reagent (Promega).
6. Plates were covered with gasket lids and incubated for 10 minutes at room temperature.
7. Luminescence was measured on a ViewLux plate reader (PerkinElmer).
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent cytotoxic compounds are ranked higher than compounds that showed no activity.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000062652 uMActivity at 0.0000234000 uMActivity at 0.0000299754 uMActivity at 0.0000680318 uMActivity at 0.0001469781 uMActivity at 0.0003237363 uMActivity at 0.0006761082 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00486 uMActivity at 0.00759 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.177 uMActivity at 0.356 uMActivity at 0.588 uMActivity at 1.402 uMActivity at 1.903 uMActivity at 4.972 uMActivity at 9.253 uMActivity at 17.29 uMActivity at 44.98 uMActivity at 91.90 uMActivity at 155.1 uMActivity at 231.0 uMCompound QC
Cytotoxic0.016689.527684Complete curve; high efficacy-7.77952.09370.944225.8586115.3863-1.10 0 0 0 0 0 0 0 0 0 05.6755108.6505117.9375108.116652.745348.993823.989228.850825.686529.035727.31935.6755QC'd by MedChem Express
Cytotoxic0.0281.223183Complete curve; high efficacy-7.69920.80.972316.819798.0429-1.10 0 0 0 0 0 08.45590.219374.545244.291328.140927.05921.55068.455QC'd by Analyticon
Cytotoxic0.032686.593783Complete curve; high efficacy-7.48620.70.95318.8792105.4729-1.10 0 0 0 0 0 08.453296.808473.066745.439734.552529.766627.43068.4532QC'd by MedChem Express
Cytotoxic0.01683.312682Complete curve; high efficacy-7.79644.95490.99689.607592.9201-1.10 0 0 0 0 0 0 09.777389.297696.418711.99539.71678.86779.754210.35039.7773QC'd by LightBiologicals
Cytotoxic0.010694.295182Complete curve; high efficacy-7.9753.1320.995511.6947105.9898-1.10 0 0 0 0 0 0 011.6947100.9198109.394435.824211.756910.793412.383613.314511.6947QC'd by Prestwick
Cytotoxic0.002788.975382Complete curve; high efficacy-8.5754.95490.99928.907497.8826-1.10 0 0 0 0 0 0 06.903497.991442.29369.96869.10388.22179.30529.09336.9034QC'd by Alfa Aesar
Cytotoxic0.008480.513982Complete curve; high efficacy-8.0754.95490.99738.893889.4076-1.10 0 0 0 0 0 0 06.357787.157291.349912.957111.042110.34028.91169.86186.3577QC'd by Bosche
Cytotoxic0.005197.54282Complete curve; high efficacy-8.2944.50450.99928.7153106.2574-1.10 0 0 0 0 0 07.9842105.047213.76299.49049.84647.65467.1497.9842QC'd by Selleck
Cytotoxic0.020694.499882Complete curve; high efficacy-7.68624.0950.998411.2634105.7632-1.10 0 0 0 0 0 010.8677105.387387.541714.414211.97659.14619.209710.8677QC'd by Selleck
Cytotoxic0.461193.529282Complete curve; high efficacy-6.33621.46410.963718.0367111.5659-1.10 0 0 0 0 0 06.0375113.1729110.6758104.027672.57924.333235.37316.0375QC'd by ChemieTek
Cytotoxic0.025983.407982Complete curve; high efficacy-7.58621.17050.994210.379993.7878-1.10 0 0 0 0 0 05.519287.484466.342228.540116.433812.144911.87075.5192QC'd by MedChem Express
Cytotoxic0.020680.277982Complete curve; high efficacy-7.68623.67720.970514.587194.865-1.10 0 0 0 0 0 07.291596.26274.959527.541914.606313.184910.65757.2915QC'd by MedChem Express
Cytotoxic0.025999.996582Complete curve; high efficacy-7.58621.11050.962710.993110.9895-1.10 0 0 0 0 0 03.5224101.819278.672730.344220.104225.11194.47963.5224QC'd by APExBIO
Cytotoxic0.014690.789582Complete curve; high efficacy-7.83621.34370.9969.109499.8989-1.10 0 0 0 0 0 06.212391.419653.831819.277613.66628.56187.43726.2123QC'd by APExBIO
Cytotoxic0.651381.720382Complete curve; high efficacy-6.18621.47870.989621.402103.1224-1.10 0 0 0 0 0 021.0506108.908195.7413101.202878.035734.663424.989321.0506QC'd by Glixx
Cytotoxic0.01384.007482Complete curve; high efficacy-7.88621.41630.994410.069994.0773-1.10 0 0 0 0 0 05.978686.088247.355717.899613.582410.519910.4225.9786QC'd by MedChem Express
Cytotoxic0.08285.068682Complete curve; high efficacy-7.08620.910.991514.09999.1676-1.10 0 0 0 0 0 010.217194.606584.923959.808127.552123.690516.789310.2171QC'd by Glixx
Cytotoxic0.006584.635382Complete curve; high efficacy-8.18624.0950.99828.850193.4854-1.10 0 0 0 0 0 06.501790.372511.997510.293910.1119.52798.25216.5017QC'd by APExBIO
Cytotoxic0.00982.724382Complete curve; high efficacy-8.0441.28760.991710.51293.2363-1.10 0 0 0 0 0 07.734485.514346.479122.47513.19099.748711.73337.7344QC'd by MedChem Express
Cytotoxic4.0E-494.19682Complete curve; high efficacy-9.3752.40640.99887.7324101.9284-1.10 0 0 0 0 0 07.3587100.769474.71979.88399.60588.64768.49037.3587QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: NTMT1-p-MTaseGlo
Protocol: Materials: NTMT1 enzyme, substrate SPKRIA, control peptide RCC1-6 is provided by the Huang laboratory.

MTaseGlo Assay:
PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION
1; Enzyme; 3 uL; Dispense enzyme mixture (final concentrations of 125 nM NTMT1 and 100 uM SAM) into Greiner 1536-well white / solid bottom assay plate (Greiner Bio One, Monroe, NC).
2; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array (Wako Automation, Richmond, VA)
3; Incubation; 15 min; Incubate at room temperature
4; Substrate; 1 uL; Dispense 1 uL of substrate at final concentration of 1 uM. Buffer solution was dispensed in control wells. The assay plate was covered with metal lids.
5; Incubation; 30 min; Incubate at room temperature, protected from lights.
6; Reagent; 1 uL; Dispensed 5x MTase-Glo detection reagent (R) into the assay plate. The plate was covered with metal lids.
7; Incubation; 30 min; Incubate the assay plates at room temperature in the dark to allow for SAH to be converted to ADP.
8; Reagent; 5 uL; Dispense 5 uL of 1x MTase-Glo Detection Solution (R) to allow for ADP to be converted to ATP which was then detected with a luciferase reaction.
9; Centrifuge; 15 sec; Centrifuge the assay plate for 15 seconds at 1000 RPM.
10; Incubation; 30 min; Assay plates were incubation at room temperature in the dark.
11; Detection; Luminescence; Plates were read on ViewLux detector (PerkinElmer). Data were normalized to no-enzyme (0% activity) and no-inhibitor (DMSO; 100%) controls, and the resulting percent inhibition data were fitted to a 4-parameter Hill equation using GraphPad Prism.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000420468 uMActivity at 0.0001060182 uMActivity at 0.0001893301 uMActivity at 0.0004489405 uMActivity at 0.0009664426 uMActivity at 0.00171 uMActivity at 0.00292 uMActivity at 0.00536 uMActivity at 0.00931 uMActivity at 0.020 uMActivity at 0.041 uMActivity at 0.085 uMActivity at 0.146 uMActivity at 0.251 uMActivity at 0.501 uMActivity at 1.073 uMActivity at 2.225 uMActivity at 4.221 uMActivity at 6.452 uMActivity at 12.64 uMActivity at 29.84 uMActivity at 57.50 uMActivity at 114.0 uMActivity at 227.6 uMActivity at 379.2 uMActivity at 573.0 uMCompound QC
Inactive0004-8.3336-1.4117-0.6141-1.80790.0446-8.3336QC'd by Sytravon
Inactive0-5.754.95490.364-29.48243.380540 0 0 0 1-1.39543.25350.7839-59.13736.0E-4-1.3954QC'd by Sytravon
Inactive0-6.753.1320.78430.870212.540 0 0 0 04.496310.2975-0.4426-1.35820.16264.4963QC'd by Sytravon
Inactive00042.0548-1.7066-2.8833-2.0050.36932.0548QC'd by Sytravon
Inactive0004-5.64220.4339-3.0268-4.4255-2.8516-5.6422QC'd by Sytravon
Inactive00040.2315-0.9193-0.962513.7196-1.97040.2315QC'd by Sytravon
Inactive0-5.054.95490.5023-0.05257.540 0 0 0 15.3132.711112.72021.5451-0.04385.313QC'd by Sytravon
Inactive00044.3883-3.3207-0.3808-0.1461-2.9714.3883QC'd by Sytravon
Inactive00045.7635-0.6995-1.72946.10241.83175.7635QC'd by Sytravon
Inactive0-4.31.06930.8616-4.25739.540 0 0 0 0-1.881111.14848.55025.98854.608-1.8811QC'd by Sytravon
Inactive0004-1.7273-3.4115-0.1881-2.6331-1.6916-1.7273QC'd by Sytravon
Inactive00044.3895-3.0627-1.10014.78020.86424.3895QC'd by Sytravon
Inactive0-54.95490.664910.50.702140 0 0 0 013.78374.4863-3.58167.22047.367813.7837QC'd by Sytravon
Inactive00046.01793.3436.89312.29364.52246.0179QC'd by Sytravon
Inactive000411.32073.08785.1642.55725.361511.3207QC'd by Sytravon
Inactive00048.73833.26642.73073.24051.84638.7383QC'd by Sytravon
Inactive0-4.052.72020.9497-18.9142-2.292240 0 0 0 0-14.0952-1.0768-4.0059-2.4795-5.6228-14.0952QC'd by Sytravon
Inactive0004-7.7765-2.2569-3.9959-1.34510.1566-7.7765QC'd by Sytravon
Inactive0-44.95490.7054-25.0658-0.540 0 0 0 0-17.5549-2.6051-3.8192-2.69936.0774-17.5549QC'd by Sytravon
Inactive0-5.84.95490.4109-5.3905440 0 0 0 0-2.49043.8042.4492-14.07540.8551-2.4904QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MCC011
Protocol: A high-throughput screen was conducted in 1536-well white flat bottom plates (Corning) on a Kalypsys robotic system. Cell lines WAGA, MKL-1, MKL-2, MCC-13, MCC-26, UISO, HaCaT, HEK293T, CRL7250, and NIH-3T3 were screened against 2 small molecule annotated drug libraries NPC and MIPE in dose response (8 and 11 pt. respectively) measuring cell viability after 72 hours of incubation. Briefly, cell lines were dissociated with trypsin or accutase (MKL-1 and MKL-2 only), passed through a 40 micron cell-strainer, and then plated with a Multidrop Combi Reagent Dispenser (ThermoFisher) into 1,536 well plates and plated down at a starting density ranging from 50 cells/ uL (HEK293T), 80 cells/ uL (NIH-3T3), 100 cells /uL (MKL-1, MKL-2, MCC-13, MCC-26, HaCaT, CRL7250, and UISO), 250 cells/ uL (WAGA) in a final volume of 5 uL of media (MCC cells: RPMI 1640, Control cells: DMEM) supplemented with 10% FBS and 1X Pen/Strep. A 1,536 pintool (Kalypsys) was used to transfer 23 nL of compound in DMSO to the 1,536-well assay plates. After 72 hr incubation at 37 degree celsius, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a BiorapTR. Plates were incubated at room temperature for 10 min, transferred to a ViewLux (PerkinElmer) and the luminescence was recorded using an exposure time of 2 seconds. Relative luminescence units (RLUs) were normalized to in-plate controls (no cells as a positive (cytotoxicity) control, DMSO as negative control) and the normalized data was processed using NCATS in-house software.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000059000 uMActivity at 0.0000296505 uMActivity at 0.0000627629 uMActivity at 0.0001361338 uMActivity at 0.0003144137 uMActivity at 0.0006678285 uMActivity at 0.00124 uMActivity at 0.00266 uMActivity at 0.00558 uMActivity at 0.00707 uMActivity at 0.017 uMActivity at 0.031 uMActivity at 0.069 uMActivity at 0.181 uMActivity at 0.368 uMActivity at 0.597 uMActivity at 1.656 uMActivity at 1.863 uMActivity at 4.836 uMActivity at 9.224 uMActivity at 16.10 uMActivity at 45.96 uMActivity at 92.69 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uM
Inhibitor37.2212127.575310Single point of activity-4.42924.95490.9931-128.5776-1.0023-30 0 0 0 0 0 0 0 0 0 0-97.40730-4.332400
Inactive0.01329.42330-7.87920.70.50130.57671040 0 0 0 0 0 0 0 0 0 01.93587.145312.24143.02923.39297.25620.5823-2.85275.4621-1.3525-0.54921.9358
Inactive0.05933.8540-7.22920.40.62832.5-1.35440 0 0 0 0 0 0 0 1 0 17.57680.82459.716.2951-2.79521.778223.810718.618626.701-8.723728.99317.5768
Inhibitor37.221243.146710Single point of activity-4.42924.95490.9703-43.14670-30 0 0 0 0 0 0 0 0 0 0-32.62230000
Inactive00004-2.32246.8981-3.111413.08049.03891.9974.8517-1.51738.13746.73713.5409-2.3224
Inhibitor37.221295.834310Single point of activity-4.42924.95490.9646-96.6556-0.8213-30 0 0 0 0 0 0 0 0 0 0-73.22402.0597-7.5145-4.9351
Inactive00004-5.924613.9115-2.239922.3817-3.690217.64660.983-10.40496.39419.0991-4.1342-5.9246
Inhibitor26.350682.76740Partial curve; partial efficacy-4.57924.0950.8717-86.5714-3.8044-2.20 0 0 0 0 0 0 0 0 0 0-78.842-5.93801.3974-28.1211
Inactive000040.022410.248810.425-3.06316.088911.75171.77591.22993.8630.57482.4410.0224
Inactive3.31737.88330-5.47924.95490.5098-2.8833540 0 0 0 0 0 0 0 0 0 0-5.73613.93155.0136.2883-1.901311.20266.12033.29585.5784-2.02860.5573-5.7361
Inactive37.221215.87970-4.42924.95490.5221-17.3797-1.540 0 0 0 0 0 0 0 0 0 0-13.2331-1.0197-4.23261.5878-1.3704
Inactive0.06627.93390-7.17920.90.59320.56618.540 0 0 0 0 0 0 0 0 0 01.56674.512510.965311.77192.24175.45342.31084.412-1.6116-0.46240.62181.5667
Inactive0.132125.77010-6.87924.95490.559-15.700910.069240 0 0 0 0 0 0 0 0 0 0-20.7968-1.38432.39852.132723.511324.9349-16.09082.2208-21.3286-30.7571-5.6999-20.7968
Inactive000040-2.3996-4.4114-2.0746-4.8678
Inactive0.66194.58310-6.17922.72020.3338-1.08313.540 0 0 0 0 0 0 0 0 0 14.56861.8671-0.85384.05730.46459.58014.53941.4181-0.6516-1.3193-0.67644.5686
Inactive000040-0.800500.13270.7944
Inactive0000414.25472.5411.436-2.13565.219813.942315.81650.97664.85062.1093-0.697614.2547
Inactive000040-49.4569-14.24420-2.3916
Inactive0.833321.05840-6.07921.37230.9479-17.0584440 0 0 0 0 0 0 0 0 0 1-3.30275.89232.6361.32297.05843.94520.8401-3.7291-9.8453-18.382-14.8977-3.3027
Inactive000040.99194.0284.60455.0511-2.99924.45879.54511.8796-2.51456.0782-1.32220.9919
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CIB1-p1-p2
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 3 uL; Protein or buffer (4/3x)
2; Compound; 46 nL; Control inhibitor / compound library
3; Time; 15 min; Room temperature incubation
4; Reagent; 1 uL; Fluorescent labeled peptide (4x)
5; Time; 1000 rpm; Centrifuge
6; Time; 15 min; Room temperature incubation
7; Detection; Ex 480/ Em 540; ViewLux Fluorescence Read

NOTES (numbers refer to sequence above)
1; Protein Mixture: C1B1-GST (final concentrations of 1 uM). Buffer composition: 5 mM HEPES pH 7.4, 125 mM NaCl, 5 mM CaCl2, 0.01% Tween20.
2; Control Inhibitor: unlabeled peptide (final concentration range 17.4 nM to 572 uM). Compound Library final concentration range 18.3 nM to 114 uM.
3; Room temperature incubation.
4; Fluorescent Labeled Peptide: FITC-aIIb (final concentration of 100 nM). Sequence of alphaIIb peptide: Acetyl-LVLAMWKVGFFKRNRK-FITC (purity is 95.83%).
5; Centrifuge 1000 rpm (164 g) for 15 seconds.
6; Room temperature incubation.
7; ViewLux Fluorescent Polization Read: excitation = 480(20) / emission = 540(25) S and P; FITC Dichroic mirror.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0002019424 uMActivity at 0.0004510146 uMActivity at 0.0009668607 uMActivity at 0.00168 uMActivity at 0.00290 uMActivity at 0.00509 uMActivity at 0.00877 uMActivity at 0.025 uMActivity at 0.041 uMActivity at 0.083 uMActivity at 0.136 uMActivity at 0.247 uMActivity at 0.490 uMActivity at 1.070 uMActivity at 2.238 uMActivity at 4.221 uMActivity at 6.448 uMActivity at 12.37 uMActivity at 30.23 uMActivity at 57.68 uMActivity at 114.0 uMActivity at 227.8 uMActivity at 383.5 uMActivity at 573.0 uMCompound QC
Inactive00043.79243.150.9632.38293.40883.72213.7924QC'd by MedChem Express
Inactive00041.27893.51021.5281.92384.63466.41821.2789QC'd by Selleck
Inactive00040.0037-4.4248-0.615-1.2841-0.0588-4.05140.0037QC'd by Selleck
Inactive0004-3.0131-5.3427-2.388-5.1553-1.5524-1.7506-3.0131QC'd by Selleck
Inactive00043.3730.82350.03162.1071.7002-1.91383.373QC'd by Selleck
Inactive00042.2123-4.94820.01822.4902-0.04663.47292.2123QC'd by Selleck
Inactive0004-6.8722-2.3397-1.6401-4.488-0.7912-2.054-6.8722QC'd by Selleck
Inactive00042.68872.97954.87572.02642.29024.4582.6887QC'd by MedChem Express
Inactive0004-3.8031-1.1794-1.5257-1.59471.0625-2.7807-3.8031QC'd by Selleck
Inactive0004-10.2079-6.2462-2.2383-3.1976-2.6796-7.2482-10.2079QC'd by Selleck
Inactive00043.20441.15581.27971.8267-0.40880.06273.2044QC'd by Analyticon
Inactive0004-8.9309-1.3351-3.9232-1.9433-5.1495-5.1305-8.9309QC'd by Analyticon
Inactive0004-2.583-2.8916-5.1264-4.8462-1.10660.1205-2.583QC'd by Analyticon
Inactive0004-2.75110.2404-3.0231-3.8049-6.48331.0107-2.7511QC'd by Analyticon
Inactive0004-4.5021.02690.00121.26520.39560.7999-4.502QC'd by Analyticon
Inactive00042.29161.59671.72554.12930.66291.2592.2916QC'd by Analyticon
Inactive00043.0438-1.4768-0.49070.27762.287-0.85233.0438QC'd by Analyticon
Inactive0004-4.3119-0.9159-1.5721-0.78780.5085-2.4781-4.3119QC'd by Analyticon
Inactive00041.0585.28035.28657.895410.16324.55741.058QC'd by Analyticon
Inactive00042.9292-2.6967-2.5902-0.50822.84874.3512.9292QC'd by Analyticon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: GPx1-biochemical-p4-p7
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Reagent 1; 3 uL; GPx1 enzyme or no enzyme control in 1536-well, black, solid Greiner assay plate.
2; Compound; 25 nL; Kalypsis pin tool (Wako USA) equipped with a 1536-well pin head.
3; Incubation; 30 min; room temperature.
4; Reagent 2; 1 uL; 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA substrate
5; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.
6; Incubation; 15 min; room temperature.
7; Detection; Fluorescence; ViewLux microplate reader, excitation 340 nm and emission 450 nm.

NOTES (numbers refer to Sequence numbers above)
1. 3 uL of 16.66 nM GPX1 and 0.016% BSA in assay buffer (50 mM Tris-HCl, 2 mM EDTA (pH 7.5), 150 mM NaCl) was added to columns 3-48 of 1536-well assay plates using a BioRAPTR Flying Reagent Dispenser (Let's Go Robotics (LGR), Carlsbad, CA). A no-enzyme control (0.01% BSA in TES assay buffer) was added to columns 1-2.
2. 25 nL of test compounds and DMSO controls were added to each well with a pin tool (Kalypsys).
3. The assay plates were incubated for 30 minutes at room temperature.
4. 1 uL of master mix (500 nM glutathione reductase (GR), 5 mM reduced glutathione (GSH), 2.5 mM NADPH in assay buffer) was added. 1 uL of cumene hydroperoxide (CHP) ([2.5 mM] in 50% EtOH) was then added within 5 minutes to initiate the reaction. Final concentrations were: 10 nM GPX1, 1 mM GSH, 0.5 mM CHP, 0.5 mM NADPH, 100 nM GR, 0.01% BSA.
5. Initial fluorescence readout (t=0) at 340/450 nm was measured using a ViewLux multimodal detector (PerkinElmer, Waltham, MA).
7. Endpoint fluorescence readout (t=15) at 340/450 nm was measured 15 min after room temperature incubation.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000080000 uMActivity at 0.0000294000 uMActivity at 0.0000322389 uMActivity at 0.0000640000 uMActivity at 0.0001602685 uMActivity at 0.0003305803 uMActivity at 0.0007029698 uMActivity at 0.00145 uMActivity at 0.00305 uMActivity at 0.00484 uMActivity at 0.00883 uMActivity at 0.016 uMActivity at 0.036 uMActivity at 0.076 uMActivity at 0.127 uMActivity at 0.227 uMActivity at 0.400 uMActivity at 1.089 uMActivity at 1.958 uMActivity at 4.491 uMActivity at 9.517 uMActivity at 15.29 uMActivity at 27.66 uMActivity at 48.83 uMActivity at 98.28 uMActivity at 150.0 uMCompound QC
Inhibitor1.153584.01186Complete curve; high efficacy-5.9382.95230.9935-85.511-1.5-1.10 0 0 0 0 0 1000.55170-10.1942-66.3862-86.37470QC'd by MedChem Express
Inhibitor4.0381107.130985Complete curve; high efficacy-5.39381.10.9833-107.6309-0.5-1.10 0 0 0 0 0 0-99.10763.0643-3.35612.7295-17.6643-28.702-81.8703-99.1076QC'd by Prestwick
Inhibitor4.5309100.661985Complete curve; high efficacy-5.34381.46410.9928-111.2365-10.5746-1.10 0 0 0 0 0 0-102.4277-6.7289-14.1368-11.7774-11.5064-34.358-88.9997-102.4277QC'd by Glixx
Inhibitor3.207694.995685Complete curve; high efficacy-5.49381.69240.997-110.0264-15.0308-1.10 0 0 0 0 0 0-108.5073-10.859-15.7072-17.8113-19.7979-44.1871-99.3353-108.5073QC'd by MedChem Express
Inhibitor3.207694.333585Complete curve; high efficacy-5.49381.55790.9917-98.6297-4.2962-1.10 0 0 0 0 0 0-97.268-10.9671-0.2469-8.8219-8.6028-35.074-85.0291-97.268QC'd by Vitas
Inhibitor4.0381101.224485Complete curve; high efficacy-5.39382.24810.9999-101.22440-1.10 0 0 0 0 0 0-101.0224000.6663-1.57-17.0563-89.6716-101.0224QC'd by DC Chemicals
Inhibitor4.5309102.529384Complete curve; high efficacy-5.34381.88510.9958-104.0293-1.5-1.10 0 0 0 0 0 0-100.803500-6.96670.0183-19.6985-87.3271-100.8035QC'd by MedChem Express
Inhibitor5.152590.153784Complete curve; high efficacy-5.2881.96730.9895-98.5024-8.3487-1.10 0 0 0 0 0 0-96.571-12.4368-8.9031-14.8602-3.6239-19.2852-77.5914-96.571QC'd by EMD Chemicals
Inhibitor6.496.476183Complete curve; high efficacy-5.19383.92950.9988-94.97611.5-1.10 0 0 0 0 0 0-95.357503.3535002.0026-79.8012-95.3575QC'd by Microsource
Inhibitor6.489.09983Complete curve; high efficacy-5.19384.44950.9997-88.5990.5-1.10 0 0 0 0 0 0-88.422200.5042.224300-77.8921-88.4222QC'd by SigmaAldrich
Inhibitor4.0928572.588765Partial curve; high efficacy-5.3882.90231-572.58870-2.10 0 0 0 0 0 100000-52.3008-521.48330QC'd by Microsource
Inhibitor2.547977.642365Complete curve; partial efficacy-5.59384.50450.9919-92.3162-14.6738-1.20 0 0 0 0 0 0-90.5524-12.7147-12.5699-11.8115-21.2763-34.6101-93.8172-90.5524QC'd by SIGMA
Inhibitor2.023979.203365Complete curve; partial efficacy-5.69381.1110.9975-92.0986-12.8952-1.20 0 0 0 0 0 0-89.2428-13.3008-14.4831-11.996-25.7417-51.5286-82.1843-89.2428QC'd by SIGMA
Inhibitor2.547939.753164Complete curve; partial efficacy-5.59384.50450.9617-72.8813-33.1282-1.20 0 0 0 0 0 0-68.5285-37.2443-35.4912-31.4131-28.8568-43.7703-77.3346-68.5285QC'd by Microsource
Inhibitor5.7812259.6350Partial curve; high efficacy-5.2381.69240.9999-259.630-2.10 0 0 0 0 0 0-250.1252000-1.0316-34.0768-179.1962-250.1252QC'd by Adooq
Inhibitor4.0928222.462650Partial curve; high efficacy-5.3882.58840.9995-221.46261-2.10 0 0 0 0 0 100003.8047-24.8352-196.33210QC'd by Glixx
Inhibitor18.0377742.537649Partial curve; high efficacy-4.74382.72021-741.53761-2.10 0 0 0 0 0 0-698.2464003.833500-124.2034-698.2464QC'd by Vitas
Inhibitor16.0761622.503649Partial curve; high efficacy-4.79382.25261-622.50360-2.10 0 0 0 0 0 0-576.39220000-5.8017-157.3588-576.3922QC'd by Glixx
Inhibitor16.0761415.830746Partial curve; high efficacy-4.79382.25260.9995-418.3307-2.5-2.10 0 0 0 0 0 0-387.3433-6.004500-3.7575-3.0222-113.565-387.3433QC'd by SIGMA
Inhibitor16.2936426.190146Partial curve; high efficacy-4.7882.72020.9998-425.69010.5-2.10 0 0 0 0 0 0-400.838100003.5739-74.4409-400.8381QC'd by MedChem Express
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:FH fumarate hydratase [Homo sapiens (human)]
External ID: FUM001
Protocol: Assay Protocol Summary:

For primary high-throughput screen, 3 ul of FH solution (containing 13.33nM human fumarate hydratase, 13.33IU/ml malic dehydrogenase, 0.2mM NAD, 0.067mg/ml diaphorase and 0.067mM resazurin in the assay buffer (50 mM Tris pH 8.0, 5 mM MgCl2, 0.01% Brij 3) was dispensed into each well in a black solid bottom 1536-well assay plate (Greiner Bio-One) using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). A 1536-well pintool dispenser outfitted with 20 nl pins (Wako Automation, San Diego, CA) was used to transfer 20 nL of DMSO-solubilized compound (Cherrypick plates) to each 1536-well assay plate. Each compound was screened at five concentrations: 15 nM, 151 nM, 1.5 uM, 15.4 uM, 76.9 uM. Following compound transfer, plates were incubated in room temperature for 10 minutes. 1 uL of substrate solution containing fumaric acid (160 uM) was dispensed via BioRAPTR FRD to initiate the reaction. Plates were immediately transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and any resulting resorufin fluorescence was measured (exitation/emission, 525/598 nm) at 0 and 15 minutes. The exposure time is 1 second. Fluorescence from each well was normalized using enzyme-free and DMSO-treated control wells on each plate, and changes in fluorescence (delta RFU) were calculated using the difference in fluorescent signal for each well at 15 minutes versus 0 minutes.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000077118 uMActivity at 0.0000393017 uMActivity at 0.0000781896 uMActivity at 0.0001700349 uMActivity at 0.0003854776 uMActivity at 0.0008323078 uMActivity at 0.00150 uMActivity at 0.00316 uMActivity at 0.00511 uMActivity at 0.00966 uMActivity at 0.023 uMActivity at 0.050 uMActivity at 0.101 uMActivity at 0.217 uMActivity at 0.414 uMActivity at 0.673 uMActivity at 1.904 uMActivity at 2.793 uMActivity at 6.307 uMActivity at 13.45 uMActivity at 20.56 uMActivity at 53.33 uMActivity at 79.85 uMActivity at 162.3 uMActivity at 288.0 uMCompound QC
Inhibitor39.810753.320210Single point of activity-4.42.58840.9867-48.82024.5-30 0 0 0 0 0 0-40.68358.16034.08673.42765.11961.6393-0.0748-40.6835QC'd by Tocris
Inactive00040.015-0.2175-0.5756-1.11951.4974-1.0976-0.62120.015QC'd by Tocris
Inactive00040.51856.07790.55083.89162.59841.17222.06630.5185QC'd by Tocris
Inactive0004-2.0257-0.374-1.4506-1.3016-1.0656-0.92350.4464-2.0257QC'd by Tocris
Inactive0-4.34.50450.984-19.1975040 0 0 0 0 0 0-16.8312-0.2154-1.25580.97381.1829-0.1066-0.0366-16.8312QC'd by Tocris
Inactive00042.12962.96550.6465-1.98581.5085-0.08872.97092.1296QC'd by Tocris
Inactive0-4.41.85790.925-12.343440 0 0 0 0 0 0-8.61915.77951.93763.81995.45582.78381.8259-8.6191QC'd by Tocris
Inactive0004-2.0918-0.9895-2.4108-0.8469-0.967-2.0746-1.3704-2.0918QC'd by Tocris
Inactive00040.0255-0.62830.01560.1788-0.8044-1.3186-0.71530.0255QC'd by Tocris
Inactive00040.1146-2.8935-5.1856-5.7517-1.454-4.3451-6.17830.1146QC'd by MedChem Express
Inactive00043.8877-1.3858-16.616.97627.2289-13.88265.81453.8877QC'd by APExBIO
Inactive0004-3.262-4.18111.5622-0.0496-1.6578-0.2741-0.8617-3.262QC'd by Tocris
Inactive0-5.354.0950.9664-6.7999440 0 0 0 0 0 15.4374.94434.753.1663.05912-6.49995.437QC'd by Axon Medchem
Inactive0004-6.3793-1.7899-0.6034-0.4471-1.1982-1.16121.5608-6.3793QC'd by Tocris
Inactive0-4.750.80.915918-3.010640 0 0 0 0 0 013.5846-2.6459-2.5886-1.4907-4.59224.02455.379313.5846QC'd by MedChem Express
Inactive0004-0.1718-2.7451-1.5974-2.775-1.4013-1.0798-0.4332-0.1718QC'd by Tocris
Inactive0-4.254.95490.9713-25.1804-1.752740 0 0 0 0 0 0-20.9837-0.8831-2.3367-0.2106-1.3606-4.0325-0.9729-20.9837QC'd by Axon Medchem
Inactive0-4.451.64360.46727.5-7.674340 0 0 0 0 0 04.0193-6.5695-2.9715-6.8641-16.8119-3.3436-5.01744.0193QC'd by Axon Medchem
Inactive0004-8.0397-4.2819-2.9052-2.785-0.42681.6569-0.2368-8.0397QC'd by Tocris
Inactive00043.3582.45981.05123.37720.91660.32320.16613.358QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: CPF001
Protocol: HEK 293, NIH 3T3, CRL-7250, HACAT and KB 3-1 cells were seeded into white 1536-well plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 250, 400, 500, 500, 500 cells/well in 5 uL of medium respectively. A pintool (Kalypsys) was used to transfer 23 nL of compound solution to the 1536-well assay plates. After 48 or 72 hr incubation at 37 degree celcius, 5% CO and 95% humidity, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a dispenser (Aspect Automation, St. Paul, MN) with solenoid valves (Lee Valves, Westbrook CT). Plates were left at room temperature for 10 min before imaging the ATP-coupled luminescence using a ViewLux microplate imager (PerkinElmer, Waltham, MA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.176 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.372 uMActivity at 1.908 uMActivity at 4.964 uMActivity at 9.273 uMActivity at 17.43 uMActivity at 44.77 uMActivity at 91.96 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000073700 uMActivity at 0.0000316373 uMActivity at 0.0000755538 uMActivity at 0.0001736587 uMActivity at 0.0003606937 uMActivity at 0.0007618542 uMActivity at 0.00133 uMActivity at 0.00262 uMActivity at 0.00635 uMActivity at 0.00856 uMActivity at 0.017 uM
Inactive0-6.08624.95490.8467-19.0684-1.540 0 0 0 0 0 12.118100-8.34361.8417-20.8904-17.20922.1181
Inactive00043.093704.02863.4263-3.42834.65930.95863.0937
Inactive0-8.43624.95490.60020-10.442940 0 0 0 0 0 1-5.6741-7.8694.8276000-3.665-5.6741
Inactive0004-1.22691.59440.8268-6.8139003.009-1.2269
Inactive00040000.646
Inactive00042.016104.739100.507404.00372.0161
Inactive00040-58.9387-0.658900.7761-3.050100
Inactive0-5.38623.57220.9641-17.9156140 0 0 0 0 0 10001.05953.84450-17.0130
Inactive0004-1.61750000-31.91564.5285-1.6175
Inactive000403.5826.95880
Inactive00044.1629-0.06810-0.13403.503204.1629
Inactive00040.0775-4.4477004.2892-3.083200.0775
Inactive0004-4.2864-6.2990000-3.464-4.2864
Inhibitor20.230130.466710Partial curve; partial efficacy; poor fit-4.6944.95490.9513-30.9667-0.5-2.40 0 0 0 0 0 0-27.47223.59671.00910-2.7438-3.3305-0.4297-27.4722
Inactive000406.34610
Inactive0004-5.47750-1.336404.40630-3.1548-5.4775
Inactive00042.2138-0.3090-3.3277-5.07761.864902.2138
Inactive0004-6.8569-2.008600000-6.8569
Inhibitor20.2301111.05610Single point of activity-4.6944.95490.9964-109.52221.5338-30 0 0 0 0 0 0-97.61333.530.1744-1.61494.641802.914-97.6133
Inactive0-4.6944.95490.8369-20.4658340 0 0 0 0 0 0-17.88822.63860
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR001
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inactive000406.942202.372800.458305.80229.8216000QC'd by BIOMOL
Inactive00040000.78791.0771004.091704.998300QC'd by BIOMOL
Inactive0-7.37924.95490.41460.86115.540 0 0 0 0 0 0 0 0 0 01.837309.11175.53448.2389002.305104.4881-0.94911.8373QC'd by BIOMOL
Inactive0-5.17922.72020.8215-20.66392.540 0 0 0 0 0 0 0 0 0 1-6.09160-2.79660.22858.08152.5833.73547.32021.7166-5.5554-18.8865-6.0916QC'd by BIOMOL
Inactive00043.74957.22936.37145.613507.482901.69948.4113003.7495QC'd by BIOMOL
Inactive00046.36577.19537.3079001.87945.979907.4799006.3657QC'd by BIOMOL
Inhibitor14.81835.514921Partial curve; partial efficacy-4.82923.06540.9214-31.01494.5-2.20 0 0 0 0 0 0 0 0 0 0-30.42915.77728.87813.66834.2274.72228.01864.5719-4.21873.6532-13.8256-30.4291QC'd by BIOMOL
Inactive000405.78175.8939008.5995006.074406.5850QC'd by BIOMOL
Inactive0004-2.104508.25230-2.17247.221607.3601-2.8223-6.14464.4899-2.1045QC'd by BIOMOL
Inactive0-4.42924.95490.4721-18.4451.540 0 0 0 0 0 0 0 0 0 0-13.287507.01614.53755.0482005.2422-2.8732-8.90186.1541-13.2875QC'd by BIOMOL
Inactive00049.43850000.93210.52520009.489409.4385QC'd by BIOMOL
Inactive0004-1.189406.558504.48600.538104.86393.46642.4738-1.1894QC'd by BIOMOL
Inactive0-6.07924.95490.40475.50.155340 0 0 0 0 0 0 0 0 0 101.4724.5108000-2.787208.386408.06150QC'd by BIOMOL
Inactive0004000.71730.66792.56178.0704009.810508.97310QC'd by BIOMOL
Inactive00041.1339-2.329408.3935009.78267.57146.4163001.1339QC'd by BIOMOL
Inactive0-9.02924.95490.38982-12.787140 0 0 0 0 0 0 0 0 0 1-4.0609-8.98923.4212-1.75787.17160.61375.21776.7693.1957-7.1191-0.2144-4.0609QC'd by BIOMOL
Inhibitor20.931101.63441Partial curve; high efficacy-4.67924.0950.99-99.56492.069-2.10 0 0 0 0 0 0 0 0 0 0-91.68045.251107.629403.87461.2696000-20.7764-91.6804QC'd by BIOMOL
Inactive000402.320402.28163.4121.25641.61620000.22870QC'd by BIOMOL
Inactive0-4.57924.50450.7778-24.88853.540 0 0 0 0 0 0 0 0 0 0-22.82385.74268.64626.02173.77214.16569.06293.0606-1.1003-6.03351.2279-22.8238QC'd by BIOMOL
Inhibitor33.1734109.831210Single point of activity-4.47924.95490.9783-109.32610.505-30 0 0 0 0 0 0 0 0 0 0-91.5629-0.0109-1.05751.09492.26989.4465-3.45940-7.435400-91.5629QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR002
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inhibitor4.109535.955421Complete curve; partial efficacy-5.38621.47870.9847-33.45542.5-1.20 0 0 0 0 0 0-32.46282.18335.970600-5.6126-25.295-32.4628QC'd by Axon Medchem
Inhibitor14.58134.657110Partial curve; partial efficacy; poor fit-4.83622.33320.9403-32.15712.5-2.40 0 0 0 0 0 0-29.71430007.41155.8195-6.9018-29.7143QC'd by Tocris
Inactive0-4.83621.86170.9256-16.65942.540 0 0 0 0 0 0-14.71612.62120.581.02516.28291.7864-3.3449-14.7161QC'd by Glixx
Inhibitor1.63666.161564Complete curve; partial efficacy-5.78622.72020.9997-65.81160.3499-1.20 0 0 0 0 0 0-66.50140000-37.9408-64.7373-66.5014QC'd by Glixx
Inactive0-4.63621.96730.7584-23.667-2.467140 0 0 0 0 0 0-19.3058-0.694-0.3893-3.2758-10.1148-2.3842-5.3061-19.3058QC'd by SIGMA
Inactive0-4.78623.06541-20.0675040 0 0 0 0 0 0-19.222900000-2.9492-19.2229QC'd by Axon Medchem
Inhibitor10.322547.836221Partial curve; partial efficacy-4.98621.88510.9724-41.83626-2.20 0 0 0 0 0 0-38.7819.20936.095507.71415.1385-14.8631-38.781QC'd by MedChem Express
Inactive00046.01782.42486.41361.896906.213206.0178QC'd by Tocris
Inhibitor29.092960.09310Single point of activity-4.53624.95491-60.03460.0584-30 0 0 0 0 0 0-54.4164000000-54.4164QC'd by Tocris
Inactive0004-6.543200000-1.4393-6.5432QC'd by Tocris
Inhibitor16.360136.851110Partial curve; partial efficacy; poor fit-4.78621.010.8986-32.35114.5-2.40 0 0 0 0 0 0-23.62598.789708.696100-7.2303-23.6259QC'd by Tocris
Inactive00049.2406001.75143.496707.9269.2406QC'd by Glixx
Inhibitor9.233.715210Partial curve; partial efficacy; poor fit-5.03621.41630.9706-30.21523.5-2.40 0 0 0 0 0 0-27.26265.31472.675106.30420-12.9935-27.2626QC'd by Tocris
Inhibitor16.360152.695221Partial curve; partial efficacy-4.78621.28760.9602-49.04213.653-2.20 0 0 0 0 0 0-37.79029.1493005.18520-13.7877-37.7902QC'd by Tocris
Inactive0-4.78624.44950.9565-27.1196340 1 0 0 0 0 0-26.76640-80.85495.97525.378600.9575-26.7664QC'd by Tocris
Inhibitor0.580574.818526Complete curve; partial efficacy-6.23623.67720.9839-72.75452.064-1.20 0 0 0 0 0 0-64.73751.50932.14072.7381-9.5317-70.5587-81.6221-64.7375QC'd by MedChem Express
Inhibitor18.356499.324110Single point of activity-4.73623.62720.9917-97.78141.5427-30 0 0 0 0 0 0-94.201708.64420-1.04460-6.3447-94.2017QC'd by Tocris
Inhibitor29.092985.830210Single point of activity-4.53624.95490.9979-84.3311.4991-30 0 0 0 0 0 0-76.60620.5645002.14332.14953.4024-76.6062QC'd by MedChem Express
Inhibitor12.995349.172121Partial curve; partial efficacy-4.88622.25260.9678-45.67253.4996-2.20 0 0 0 0 0 0-42.17617.83150.28501.26966.3138-12.2728-42.1761QC'd by Tocris
Inactive0-4.68621.88510.8683-38.0965-12.016740 0 0 0 0 0 0-33.4065-7.5139-13.5025-14.684-16.035-8.8732-16.7676-33.4065QC'd by Selleck